Crescentis Capital re-appoints MD and CEO for five years
Crescentis Capital Limited's board has approved the re-appointment of Mr. Subba Rao Veera Venkata Meka as Managing Director and Mr. Bhavanam Ruthvik Reddy as Whole-Time Director & CEO for a term of five years starting September 12, 2026. The re-appointments are subject to shareholder approval at the ensuing general meeting. The decisions follow recommendations by the Nomination and Remuneration Committee.

*this image is generated using AI for illustrative purposes only.
Crescentis Capital Limited has approved the re-appointment of its Managing Director and Whole-Time Director & CEO for a further term of five years starting September 12, 2026. The board's decision, taken on May 29, 2026, follows the recommendation of the Nomination and Remuneration Committee. These re-appointments are subject to the approval of shareholders at the ensuing general meeting and other statutory approvals.
Mr. Subba Rao Veera Venkata Meka has been re-appointed as Managing Director. His current term concludes at the close of business hours on September 11, 2026. Mr. Bhavanam Ruthvik Reddy has been re-appointed as Whole-Time Director & Chief Executive Officer, with his current term also ending on September 11, 2026. Both directors will serve for a period of five years from September 12, 2026.
The disclosure confirms there are no inter-se relationships between Mr. Subba Rao Veera Venkata Meka and other board members or senior management. However, Mr. Bhavanam Ruthvik Reddy is related to Mr. Bhaskara Rao Bollineni.
Director Profiles
Mr. Subba Rao Veera Venkata Meka brings over four decades of experience in domestic and international banking. He previously worked with Syndicate Bank, ABN AMRO, and The Royal Bank of Scotland (RBS). Since joining Crescentis Capital as Managing Director in September 2023, he has steered the company's transition from an investment-holding entity to an active Non-Banking Financial Company (NBFC).
Mr. Bhavanam Ruthvik Reddy holds a B.Tech in Civil Engineering and has over nine years of experience in business strategy and financial services. He has been associated with Krishna Institute of Medical Sciences (KIMS) since 2017. Serving as Whole-Time Director & CEO since September 12, 2023, he played a key role in commencing the company's NBFC operations in June 2025.
Re-appointment Details
| Particulars | Mr. Subba Rao Veera Venkata Meka | Mr. Bhavanam Ruthvik Reddy |
|---|---|---|
| Designation | Managing Director | Whole-Time Director & CEO |
| Current Term End | September 11, 2026 | September 11, 2026 |
| Re-appointment Date | September 12, 2026 | September 12, 2026 |
| Term | Five Years | Five Years |
| Relationship | None | Related to Mr. Bhaskara Rao Bollineni |
Historical Stock Returns for Crescentis Capital
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.71% | -10.23% | -13.44% | -8.58% | +6.75% | +641.31% |
What strategic milestones does Crescentis Capital aim to achieve during the new five-year term to further solidify its NBFC operations?
How will the leadership team plan to expand the company's loan book and asset base following the recent transition to an active NBFC?
What potential impact will the relationship between Mr. Reddy and Mr. Bollineni have on corporate governance and strategic decision-making?

































